On September 1, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of its Post-Market Drug Evaluation Program.
Currently, CADTH’s Scientific Advice program offers pre-market advice on early drug development plans from a Canadian health technology assessment perspective and its Reimbursement Review program provides public drug plans with reimbursement recommendations. With this program, CADTH expands its role, establishing a network of experts that will provide federal, provincial, and territorial decision-makers with information and advice regarding the safety, effectiveness, and appropriate use of approved drugs in Canada.
A key component of the program is the CoLab Network, which will consist of experts in applied research, drug evaluation methodologies, and data analysis across Canada. The network will assist decision-makers by providing timely and targeted evidence reviews based on real-world data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada publishes guidance on distinction between advertising and other activities for health products
Promotional messages and activities regarding a health product are subject to the advertising provisions under the Food and Drugs Act (FDA), the Controlled Drugs and Substances Act and/or their associ...Read More -
PMPRB news: New Vice Chairperson appointed, Meds Entry Watch 7th Ed. published
On August 15, 2023, the Minister of Health announced the appointment of Anie Perrault as Vice Chairperson of the Patented Medicine Prices Review Board (PMPRB) for a five-year term.Read More -
Updated and new draft Health Canada guidance documents related to medical devices
On August 30, 2023, Health Canada opened consultation on its draft pre-market guidance for machine learning-enabled medical devices (MLMD).Read More